The Administrative Core will provide support for each of the Projects of this P01, as well as the Metabolism/Histopathology Core (Core B).
The aims of the Administrative Core are to ensure that the resources within the P01 are distributed equitably to the investigators and all rules and regulations of the National Cancer Institute and the National Institutes of Health are followed. The Administrative Core will coordinate monthly meetings of the investigators and their laboratories, and facilitate communication between our investigators and the External Advisory Board. The Administrative Core will also coordinate the quarterly regional meetings held at Princeton University and hosted by Dr. Joshua Rabinowitz. Finally, the Administrative Core will work with the business administration office of the Abramson Family Cancer Research Institute (AFCRI) to ensure that funds are subcontracted to Memorial Sloan-Kettering Cancer Center (MSKCC) for Project 1 led by Dr. Craig Thompson. The finances of the P01 will be organized by Mr. James Riley, the AFCRI Director of Fiscal Operations, who will meet monthly with the P01 PI and quarterly with each Project and Core Leader. Ms. Dana Opiela will coordinate travel arrangements for the members of the P01, as well as the advisors who will visit U. Pennsylvania. Furthermore, Ms. Jaclyn Regan will coordinate travel arrangements for the members of the P01 located at MSKCC. Both Ms. Opiela and Ms. Regan will provide administrative support for each of the P01 investigators for efforts related to the program. It is anticipated that through the combined efforts of the Core Director (Dr. Simon), Mr. Riley, Ms. Opiela, and Ms. Regan that the research effort of this P01 will run with optimum efficiency.
As PI of this Program Project application, Dr. Celeste Simon will work closely with Ms. Dana Opiela, Administrative Assistant to this core. Moreover, Dr. Simon and Ms. Opiela will co-ordinate activities of the Program with Mr. Jim Riley, Director of Fiscal Operations at the Abramson Family Cancer Research Institute at the University of Pennsylvania, and Ms. Jaclyn Regan, laboratory Administrative Assistant to Drs. Craig Thompson and Tulia Lindsten at Memorial Sloan-Kettering Cancer Center.
|Zhang, Ji; Pavlova, Natalya N; Thompson, Craig B (2017) Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J 36:1302-1315|
|Davis, Jeremy L; Langan, Russell C; Panageas, Katherine S et al. (2017) Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. Ann Surg Oncol 24:1989-1996|
|Xie, Hong; Simon, M Celeste (2017) Oxygen availability and metabolic reprogramming in cancer. J Biol Chem 292:16825-16832|
|Rozpedek, W; Nowak, A; Pytel, D et al. (2017) Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways. Curr Mol Med 17:118-132|
|Gannon, Patrick J; Akay-Espinoza, Cagla; Yee, Alan C et al. (2017) HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via ?-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol 187:91-109|
|Ricca, Jacob; Turkekul, Mesruh; Barlas, Afsar et al. (2017) Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. Methods Mol Biol 1554:253-262|
|Sands, Stephen; Ladas, Elena J; Kelly, Kara M et al. (2017) Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Support Care Cancer 25:701-708|
|Gade, Terence P F; Tucker, Elizabeth; Nakazawa, Michael S et al. (2017) Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology 283:702-710|
|Palm, Wilhelm; Thompson, Craig B (2017) Nutrient acquisition strategies of mammalian cells. Nature 546:234-242|
|Pytel, Dariusz; Gao, Yan; Mackiewicz, Katarzyna et al. (2016) PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. PLoS Genet 12:e1006518|
Showing the most recent 10 out of 113 publications